Bone Biologics (BBLG) vs Scinai Immunotherapeutics (SCNI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Scinai Immunotherapeutics is the larger company by market cap ($1.6 million vs $1.3 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBLG | SCNI |
|---|---|---|
| Share price | $0.4691 | $1.21 |
| Market cap | $1.29M | $1.64M |
| 1-day change | -3.77% | +7.08% |
| P/E ratio (TTM) | — | 0.04 |
| EPS (TTM) | $-1.37 | $28.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.76 | $15.65 |
| 52-week low | $0.428 | $1.06 |
| Distance from 52-week high | -83.00% | -92.27% |
| Analyst consensus | none | — |
| Avg. price target upside | +2500.72% | — |
| Average volume | 378.20K | 1.10M |
| Shares outstanding | 2.76M | 1.35M |
| Employees | 2 | 45 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bone Biologics
BBLG stock →Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration.
Health Care · Industrial Specialties · 2 employees
About Scinai Immunotherapeutics
SCNI stock →Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
BBLG vs SCNI FAQ
Which is bigger, Bone Biologics or Scinai Immunotherapeutics?
Scinai Immunotherapeutics (SCNI) is larger, with a market capitalization of $1.64M compared with $1.29M for Bone Biologics (BBLG).
Are Bone Biologics and Scinai Immunotherapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Industrial Specialties for Bone Biologics and Biotechnology: Biological Products (No Diagnostic Substances) for Scinai Immunotherapeutics.